An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Appili Therapeutics announced the results of its annual general meeting held on September 7, 2021, highlighting shareholder approval of all resolutions. Josef Vejvoda has been elected to the Board of Directors, bringing over 25 years of capital markets experience. Voting results indicate strong support for board members, including Ian Mortimer and Brian Bloom, with percentages of votes for exceeding 99%. Additionally, PricewaterhouseCoopers was reappointed as the independent auditor. Appili focuses on developing novel therapies for infectious diseases, including ongoing trials for the antiviral Avigan/Reeqonus.
Positive
Elected Josef Vejvoda, a capital markets veteran, to the Board, enhancing expertise.
Shareholder voting results show strong support for board members, indicating confidence.
Reappointment of PricewaterhouseCoopers as independent auditors suggests financial stability.
Negative
None.
Capital Markets Veteran Josef Vejvoda to Join Appili Board of Directors as New Director
HALIFAX, Nova Scotia--(BUSINESS WIRE)--
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced the results from its annual general meeting of shareholders held on Tuesday, September 7, 2021. The Company also announced the addition of Josef Vejvoda to its Board of Directors (the “Board”).
Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich, Theresa Matkovits, Rochelle Stenzler, Armand Balboni, and newly elected Josef Vejvoda.
Voting results for each director are summarized below:
Name of Nominee
Percentage of Votes For
Percentage of Votes Withheld
Ian Mortimer
99.85%
0.15%
Brian Bloom
100%
0%
Juergen Froehlich
99.85%
0.15%
Theresa Matkovits
99.85%
0.15%
Rochelle Stenzler
100%
0%
Armand Balboni
100%
0%
Josef Vejvoda
100%
0%
Josef Vejvoda brings to Appili’s Board over 25 years of capital markets experience. Mr. Vejvoda currently acts as special advisor to K2 & Associates Investment Management Inc. (“K2”), a multi-strategy investment fund, and previously held senior operating executive positions at K2 as Chief Compliance Officer and Chief Executive Officer. Mr. Vejvoda has also held senior management roles at a number of the country’s largest financial institutions, including Merrill Lynch Canada, National Bank Financial, and TD Securities, as well as serving on numerous public company boards.
Mr. Vejvoda graduated from Queen’s University with a BSc in Computer Science. Mr. Vejvoda has also earned the Chartered Investment Manager (CIM®) designation from the Canadian Securities Institute and is a graduate of the Institute of Corporate Directors having achieved the ICD.D designation.
Shareholders also approved the re-appointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan/Reeqonus for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
